Laboratory: Clinical Biochemistry  (AUTOMATED)
Test Name:
TRIGLYCERIDES - (P)
Test Code: TG
Clinical Information:
Description: Used to evaluate cardiovascular risk.
 

Recommendations: Canadian Cardiovascular Society Dyslipidemia Guidelines

 

Adult: 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults

 

Pediatrics: The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update (2022)

Patient Preparation Instructions: Fasting or non-fasting specimen, as requested by the ordering physician.

 

If fasting specimen is required:

Adult: fast 8 hours

Infant: collect just before next feeding
 
Collection Devices:
Specimen Required:


Plasma: 2.0 mL
Pediatric Plasma: 0.2 mL

Specimen Stability:
Ambient: 2 days

Refrigerated: 10 days

Frozen: 3 months at -20ºC or several years at -70ºC
Referral:
Serum: 2.0 mL

Shipping & Storage: Aliquot, store and ship frozen (if testing not to be completed within 24 hours). For testing to be completed within 24 hours, ship refrigerated aliquot.
Requisition:
Reference Values:
AgeDecision LimitComment
<10 y<1.10 mmol/L

If fasting:

Desired: < 0.80 mmol/L

Borderline: 0.80 - <1.10 mmol/L

Increased risk:  >= 1.10 mmol/L

 

If nonfasting, triglycerides are, on average, elevated 20% above fasting levels, however individual patients may vary.

10-19 y<1.50 mmol/L

If fasting:

Desired: < 1.00 mmol/L

Borderline: 1.00 - <1.50 mmol/L

Increased risk:  >= 1.50 mmol/L

 

If nonfasting, triglycerides are, on average, elevated 20% above fasting levels, however individual patients may vary.

>/= 20 y<1.70 mmol/LIf nonfasting, triglycerides <2.00 mmol/L acceptable

 

If triglycerides >9.04 mmol/L, LDL-C (NIH equation) will not be calculated.

Method of Analysis: Roche Cobas or Ortho Vitros: enzymatic, colorimetric

 

 
Availability:
Stat or Routine
See Also:
More Information:
Interpretation & Assay Interferences: N-Acetylcysteine at the therapeutic concentration when used as an antidote and the acetaminophen metabolite N-acetyl-p-benzoquinone imine (NAPQI) independently may cause falsely low results.